IMMUNITYBIO, INC. Proceeds from Sale of Debt Securities, Available-for-sale
IMMUNITYBIO, INC. (IBRX) reported Proceeds from Sale of Debt Securities, Available-for-sale of $8.27 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2021-03-04
- IMMUNITYBIO, INC. proceeds from sale of debt securities, available-for-sale for the quarter ending 2020-12-31 was $1.69M.
- IMMUNITYBIO, INC. proceeds from sale of debt securities, available-for-sale for the quarter ending 2019-12-31 was $0.00.
- IMMUNITYBIO, INC. proceeds from sale of debt securities, available-for-sale for fiscal 2020 was $8.27M, a 227.09% increase from fiscal 2019.
- IMMUNITYBIO, INC. proceeds from sale of debt securities, available-for-sale for fiscal 2019 was $2.53M.
- IMMUNITYBIO, INC. proceeds from sale of debt securities, available-for-sale for fiscal 2018 was $0.00.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|
| 2020-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $8.27M 10-K · filed 2021-03-04 | |
| 2020-09-30 | $6.58M 10-Q · filed 2020-11-09 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $2.53M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $2.53M 10-Q · filed 2020-11-09 | ||
| 2018-12-31 | $0.00 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |